Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.
Othman J, Lam HPJ, Leong S, Basheer F, Abdallah I, Fleming K, Mehta P, Yassin H, Laurie J, Austin M, Gallipoli P, Taylor T, Dennis M, Elliot J, Clarke G, Dang R, Vidler J, Krishnamurthy P, Latif AL, Kalkur P, Shahidianakbar M, Campbell V, Mannari D, Sutherland E, Wickramaratne T, Collins A, Zhao R, Mak H, Belsham E, Banerjee S, Bashir J, Pillai S, Whitmill R, Galli S, Amer M, Murthy V, Murray D, Wandroo F, Hogan F, Crolla F, Fowler N, Khan A, O'Nions J, Dillon R.
Othman J, et al. Among authors: taylor t.
Blood Neoplasia. 2024 May 23;1(3):100017. doi: 10.1016/j.bneo.2024.100017. eCollection 2024 Sep.
Blood Neoplasia. 2024.
PMID: 40453057
Free PMC article.
Clinical Trial.